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Hepatic stellate cells (HSCs) represent the
major cell type involved in liver fibrosis. In
normal liver HSCs are in a quiescent state;
when the liver is damaged, stellate cells
can change into an activated state, char-
acterized by proliferation, contractility,
chemotaxis, and secretion of extracellular
matrix proteins, such as collagen, which
can lead to cirrhosis (Li et al., 2008). HSCs
are considered as “hepatic pericytes,”
because they possess protrusions that wrap
around the sinusoids and their contrac-
tion contribute to the modulation of sinu-
soidal resistance and blood flow (Soon
and Yee, 2008). Several agonists, either
paracrine or circulating, stimulate HSC
contraction; these include angiotensin-
II (ATII), endothelin-1 (ET-1), arginine-
vasopressin, thrombin, eicosanoids, and
catecholamines. Circulating levels of these
agents may be elevated in patients with
liver disease, and increased in animalmod-
els of liver injury. In particular, perfusion
of isolated rodent livers with ATII or ET-1
causes a reduction in sinusoidal diame-
ter associated to increase in portal pres-
sure, while administration of ATII or ET-1
receptor antagonists decreases portal pres-
sure (Farrell et al., 2008; Reynaert et al.,
2008). This evidence underscores the role
of agonists that increase HSC contractil-
ity in the regulation of hepatic blood flow.
On the other hand, several agents, includ-
ing nitric oxide, carbon monoxide, and
prostaglandins, may counteract the effects
of contraction-inducing stimuli by caus-
ing HSC relaxation. Nitric oxide produc-
tion is reduced in the injured liver, while
nitric oxide donors reduce portal pressure
induced by contractile stimuli in perfused
liver (Hendrickson et al., 2003; Laleman
et al., 2007). Thus, current view consid-
ers sinusoidal tone as finely modulated
by the balance between HSC relaxation
and HSC contraction. Regulation of con-
tractility status in HSC recapitulates the
general mechanism well known in vas-
cular smooth muscle cells (VSMC). In
HSC, myosin light chain phosphoryla-
tion activates myosin II and supports
contraction, whereas reduction of myosin
phosphorylation inhibits contractile force
generation. Cytosolic Ca2+ signaling may
regulate HSC contraction by activating
myosin light chain kinase, which selec-
tively phosphorylates the myosin regula-
tory light chain. Available data, however,
indicate that the contribution of Ca2+
signaling to the regulation of HSC con-
traction might be less important than in
VSMC. Instead, a critical signaling path-
way regulating myosin phosphorylation
in HSC seems to be RhoA/Rho kinase.
Rho-kinase (ROK) is a cytosolic kinase
activated by the small GTPase RhoA, link-
ing different vasoactive receptors to the
myosin light chain phosphatase (MLCP).
Activation of ROK inhibits the activity
of MLCP and thereby increases phos-
phorylation of myosin light chains. In
liver cirrhosis intrahepatic ROK is upreg-
ulated and inhibition of ROK decreases
hepatic-portal resistance and portal pres-
sure (Klein et al., 2012).
Nonalcoholic fatty liver disease
(NAFLD) is a relatively common condi-
tion, characterized by fatty accumulation
(steatosis) in the liver and related to insulin
resistance and metabolic syndrome, that
often progresses into the more serious
non-alcoholic steato-hepatitis (NASH)
and, in some cases, to cirrhosis or hepa-
tocarcinoma. The transition from NAFLD
to NASH depends on a superimposed
inflammatory mechanism, that induces
activation of HSC, injury to hepatic micro-
circulation, venous obstruction, increased
production of extracellular matrix, and
fibrous septation, (Wanless and Shiota,
2004; Bian and Ma, 2012). Activation of
HSC and subsequent vascular insult is rec-
ognized as an important pathogenic step.
Both non-pharmacological and pharma-
cological treatments have been proposed
for NAFLD and NASH, but no drug
therapies have been so far accepted as
standard therapy. Non-pharmacological
treatment includes measures to grad-
ually reduce body weight such as diet,
aerobic exercise, and bariatric surgery.
Drug treatment includes chiefly insulin
sensitizers such as metformin and thi-
azolidinediones (Musso et al., 2012).
Other drugs, that are not primarily act-
ing on liver metabolic activity, such as
angiotensin receptor blockers (ARBs),
have been also proposed (Yokohama
et al., 2004). The theoretical mecha-
nisms underlying the effectiveness of
such drug therapies are obviously diverse.
But what we want to point here is the
potential relevance of HSCs as pharma-
cological target, particularly regarding
their role in regulating the caliber of hep-
atic sinusoids and thereby portal blood
flow, perfusion pressure, and resistance.
Activation of peroxisome proliferator-
activated receptor gamma (PPARγ)
inhibits HSC collagen production and
modulates HSC adipogenic phenotype
at transcriptional and epigenetic levels
(Zhang et al., 2012). The ability of acti-
vating PPARγ-dependent gene expression
is shared by thiazolidinediones and at
least some ARBs, such as Telmisartan
and Irbesartan (Schupp et al., 2004). It
seems therefore plausible that these two
classes of drugs may share a PPARγ-
dependent action on HSC, resulting
in a non-fibrogenic quiescent pheno-
type. Moreover, besides PPARγ-mediated
effects, thiazolidinediones have been
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reported to exert PPARγ-independent
effects on smooth muscle cells and vas-
cular tone (Salomone, 2011; Salomone
and Drago, 2012) that might be exerted
also on HSC. In particular, PPARγ lig-
ands inhibit Rho/ROK pathway in vascular
tissues, by inducing the expression of pro-
tein tyrosine phosphatase SHP-2 (Wakino
et al., 2004) and cause a rapid inhibition
of myosin phosphatase target subunit 1
(MYPT1) phosphorylation in a ROK-
independent manner (Atkins et al., 2009).
Inhibitors of the renin-angiotensin sys-
tem, including ARBs, counteract liver
fibrosis, and reduce portal hyperten-
sion. The main effect of ARBs is as
antagonists of the AT1 receptor, thereby
inhibiting transformation of the qui-
escent HSC into the myofibroblast like
activated HSC and the synthesis of trans-
forming growth factor-beta1, the major
profibrotic cytokine in the liver (Tox
and Steffen, 2006). ARBs obviously also
oppose the effect of ATII on HSC con-
tractility. Thiazolidinediones and ARBs
therefore both inhibit the transition of
HSC to fibroblast-like phenotype, respon-
sible for matrix deposition and cirrhotic
outcome and decrease the contractility
status of HSC, which may have an addi-
tional effect on portal pressure and portal
blood flow. Telmisartan, beside the ATII-
dependent vascular effect, induces also, at
least in vitro, an endothelium-dependent
vasodilatation (Siarkos et al., 2011), that
may further impact hepatic blood flow
in NAFLD/NASH. Interestingly, a recent
study using high-content analysis in a rat
model predicts telmisartan and pioglita-
zone as very effective antifibrotic drugs
(Zheng et al., 2011).
In conclusion, we outline here the
importance of two drug mechanisms
targeting HSC that may be relevant
when treating NAFLD/NASH: PPARγ-
stimulation and relaxation of contrac-
tile apparatus. These two mechanisms
are likely to have different kinetics, the
first requiring gene-expression, the sec-
ond occurring as soon as the drug binds
membrane receptors and/or transduction
proteins that affect myosin phosphoryla-
tion. Therefore, beside the opposing effect
on HSC activation (such that dependent
from PPARγ), we propose that studies
should be designed to examine in vitro the
effects of isolated drugs on HSC contrac-
tility and/or, in vivo, their effect on portal
blood pressure and flow, as predictors of
efficacy for NAFLD/NASH treatment in
preclinical settings.
REFERENCES
Atkins, K. B., Irey, B., Xiang, N., and Brosius, F. C. 3rd.
(2009). A rapid, PPAR-gamma-dependent effect
of pioglitazone on the phosphorylation of MYPT.
Am. J. Physiol. Cell Physiol. 296, C1151–C1161.
Bian, Z., and Ma, X. (2012). Liver fibrogenesis in
non-alcoholic steatohepatitis. Front. Physiol. 3:248.
doi: 10.3389/fphys.2012.00248
Farrell, G. C., Teoh, N. C., and McCuskey, R. S.
(2008). Hepatic microcirculation in fatty liver dis-
ease. Anat. Rec. (Hoboken) 291, 684–692.
Hendrickson, H., Chatterjee, S., Cao, S., Morales Ruiz,
M., Sessa, W. C., and Shah, V. (2003). Influence of
caveolin on constitutively activated recombinant
eNOS: insights into eNOS dysfunction in BDL rat
liver. Am. J. Physiol. Gastrointest. Liver Physiol. 285,
G652–G660.
Klein, S., Van Beuge, M. M., Granzow, M., Beljaars,
L., Schierwagen, R., Kilic, S., et al. (2012). HSC-
specific inhibition of Rho-kinase reduces portal
pressure in cirrhotic rats without major systemic
effects. J. Hepatol. doi: 10.1016/j.jhep.2012.07.033.
[Epub ahead of print].
Laleman, W., Van Landeghem, L., Van der Elst,
I., Zeegers, M., Fevery, J., and Nevens, F.
(2007). Nitroflurbiprofen, a nitric oxide-releasing
cyclooxygenase inhibitor, improves cirrhotic por-
tal hypertension in rats. Gastroenterology 132,
709–719.
Li, J. T., Liao, Z. X., Ping, J., Xu, D., and Wang, H.
(2008). Molecular mechanism of hepatic stellate
cell activation and antifibrotic therapeutic strate-
gies. J. Gastroenterol. 43, 419–428.
Musso, G., Cassader, M., Rosina, F., and Gambino, R.
(2012). Impact of current treatments on liver dis-
ease, glucose metabolism and cardiovascular risk
in non-alcoholic fatty liver disease (NAFLD): a sys-
tematic review and meta-analysis of randomised
trials. Diabetologia 55, 885–904.
Reynaert, H., Urbain, D., and Geerts, A. (2008).
Regulation of sinusoidal perfusion in portal hyper-
tension. Anat. Rec. (Hoboken) 291, 693–698.
Salomone, S. (2011). Pleiotropic effects of glitazones:
a double edge sword? Front. Pharmacol. 2:14. doi:
10.3389/fphar.2011.00014
Salomone, S., and Drago, F. (2012). Effects of
PPARgamma ligands on vascular tone. Curr. Mol.
Pharmacol. 5, 282–291.
Schupp, M., Janke, J., Clasen, R., Unger, T., and
Kintscher, U. (2004). Angiotensin type 1 recep-
tor blockers induce peroxisome proliferator-
activated receptor-gamma activity. Circulation
109, 2054–2057.
Siarkos, I., Urso, V., Sinagra, T., Drago, F., and
Salomone, S. (2011). Endothelium-dependent
vasomotor effects of telmisartan in isolated rat
femoral arteries. Pharmacol. Res. 63, 199–206.
Soon, R. K. Jr., and Yee, H. F. Jr. (2008). Stellate cell
contraction: role, regulation, and potential thera-
peutic target. Clin. Liver Dis. 12, 791–803, viii.
Tox, U., and Steffen, H. M. (2006). Impact of
inhibitors of the Renin-Angiotensin-aldosterone
system on liver fibrosis and portal hypertension.
Curr. Med. Chem. 13, 3649–3661.
Wakino, S., Hayashi, K., Kanda, T., Tatematsu,
S., Homma, K., Yoshioka, K., et al. (2004).
Peroxisome proliferator-activated receptor gamma
ligands inhibit Rho/Rho kinase pathway by induc-
ing protein tyrosine phosphatase SHP-2. Circ. Res.
95, e45–e55.
Wanless, I. R., and Shiota, K. (2004). The pathogene-
sis of nonalcoholic steatohepatitis and other fatty
liver diseases: a four-step model including the role
of lipid release and hepatic venular obstruction in
the progression to cirrhosis. Semin. Liver Dis. 24,
99–106.
Yokohama, S., Yoneda, M., Haneda, M., Okamoto,
S., Okada, M., Aso, K., et al. (2004). Therapeutic
efficacy of an angiotensin II receptor antago-
nist in patients with nonalcoholic steatohepatitis.
Hepatology 40, 1222–1225.
Zhang, F., Kong, D., Lu, Y., and Zheng, S. (2012).
Peroxisome proliferator-activated receptor-
gamma as a therapeutic target for hepatic fibrosis:
from bench to bedside. Cell. Mol. Life Sci. doi:
10.1007/s00018-012-1046-x. [Epub ahead of
print].
Zheng, B., Tan, L., Mo, X., Yu, W., Wang, Y.,
Tucker-Kellogg, L., et al. (2011). Predicting in vivo
anti-hepatofibrotic drug efficacy based on in vitro
high-content analysis. PLoS ONE 6:e26230. doi:
10.1371/journal.pone.0026230
Received: 13 September 2012; accepted: 07 October
2012; published online: 2 October 2012.
Citation: Bucolo C, Drago F and Salomone S (2012)
Potential drug mechanism(s) targeting the contractile
status of hepatic stellate cells. Front. Pharmacol. 3:187.
doi: 10.3389/fphar.2012.00187
This article was submitted to Frontiers in Experimental
Pharmacology and Drug Discovery, a specialty of
Frontiers in Pharmacology.
Copyright © 2012 Bucolo, Drago and Salomone. This
is an open-access article distributed under the terms of
the Creative Commons Attribution License, which per-
mits use, distribution and reproduction in other forums,
provided the original authors and source are credited
and subject to any copyright notices concerning any
third-party graphics etc.
Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery October 2012 | Volume 3 | Article 187 | 2
5
